By Foo Yun Chee and Maggie Fick BRUSSELS/LONDON (Reuters) -EU antitrust regulators will decide by Dec. 6 whether to clear ...

The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...

The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of ...

Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug ...

Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.

Adds Catalent response. The CEO of Swiss pharmaceuticals behemoth Roche (OTCQX:RHHBY) said he believes antitrust regulators ...

Reports Q1 revenue $ $1.02B , consensus $1.06B…Q1’25 Adjusted EBITDA of $125 million increased 11% as reported, or 10% in constant ...

And please do keep in touch. … European Union antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings’ ...

Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | ...

European Union antitrust regulators will decide by December 6 whether to clear Novo Holdings’ acquisition of contract drug manufacturer Catalent. Catalent posted a surprise first-quarter loss and ...

(Reuters) - Contract drug manufacturer Catalent, which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.